The Cuban institution noted on Twitter the validation of the product for emergency use in pediatric population over two years of age and for those who suffered the disease after two months or more of medical discharge.
“The approval is based on the results of the clinical trial with Soberana Plus in Covid-19 convalescent children, which showed high safety markers after the administration of one dose and the benefits against the potential risk of reinfection by the SARS-CoV-2 coronavirus, which causes the disease,” according to a tweet from the IFV.
The Institute’s director of Research, Ph.D. Dagmar Garcia, pointed out that Cuba is currently overcoming the situation to the extent that all people can be vaccinated.
“We have already covered the space we had left. We have come now to another crossroad in the ‘game’, we have to see what ‘play’ the Omicron strain has in store for us now, it seems tough, and what other card the SARS-CoV-2 has up its ‘sleeve”, she wrote on her Twitter account.
She added that there was a lot of responsibility involved in recommending the Cuban Health Ministry the vaccination of children from the age of two. “Today we got the validation, so the authorization and vaccination process should begin, thanks to the results of the clinical trial,” she said.
jg/lcr/mem/cdg
